News | December 04, 2014

Mount Sinai Study Shows Vital Exhaustion May Raise Risk of Cardiovascular Disease

Fatigue, irritability and demoralization can increase risk of first-time event up to 36 percent

December 4, 2014 — Fatigue, increased irritability and feeling demoralized may raise a healthy man or woman’s risk of first-time cardiovascular disease by 36 percent, according to a study led by researchers at Mount Sinai St. Luke’s and Mount Sinai Roosevelt hospitals. Study results were presented on Nov. 17 at the American Heart Association’s Scientific Sessions 2014 in Chicago.

The combination of fatigue, increased irritability and feeling demoralized is medically known as vital exhaustion. In their study, Mount Sinai researchers found that vital exhaustion was associated with a dramatic increase in risk for first-time cardiovascular disease when compared to people not experiencing these three psychological factors.  

“Our study shows vital exhaustion is an important risk factor for the development of cardiovascular disease in otherwise healthy people,” says lead author Randy Cohen, M.D., medical director of the University Medical Practice Associates at Mount Sinai St. Luke's and Mount Sinai Roosevelt. “Loss of vitality thus adds to a growing number of psychosocial risk factors that have now been linked to the development of cardiovascular disease, including anxiety, depression and social isolation.”

Study researchers investigated the relationship between vital exhaustion and first-time heart disease in 11 prospective studies that involved 60,610 people without heart disease. The studies had an average follow-up of 6.5 years.

“The identification of vital exhaustion as a coronary artery disease (CAD) risk factor appears timely,” according to study co-author Alan Rozanski, M.D., Chief of the division of cardiology at Mount Sinai St. Luke’s and Mount Sinai Roosevelt. “As society becomes increasingly fast-paced, there is an increasing tendency for people to overwork while cutting back on sleep, exercise and the rest and relaxation we all need to renew ourselves and prevent the factors that cause vital exhaustion.”

Other study co-authors include: Jincy Thankachen, M.D., and Chirag Bavishi, M.D., of Mount Sinai St. Luke’s and Mount Sinai Roosevelt.

 

For more information: www.mountsinai.org

Related Content

Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
NIAID Scientists Illuminate Mechanism of Increased Cardiovascular Risks With HIV
News | Cardiac Diagnostics| September 14, 2017
September 14, 2017 — Scientists at the National Institutes of Health have expanded the understanding of how chronic i
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init